# FULIRI Plus Targeted Therapy for First-line Conversion Therapy of Colorectal Cancer Liver Metastases.

> **NCT07515963** · PHASE2 · NOT_YET_RECRUITING · sponsor: **Zhongnan Hospital** · enrollment: 24 (estimated)

## Conditions studied

- Colo-rectal Cancer

## Interventions

- **DRUG:** FULIRI combination targeted therapy

## Key facts

- **NCT ID:** NCT07515963
- **Lead sponsor:** Zhongnan Hospital
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** NOT_YET_RECRUITING
- **Start date:** 2026-06-01
- **Primary completion:** 2027-02-01
- **Final completion:** 2028-02-01
- **Target enrollment:** 24 (ESTIMATED)
- **Last updated:** 2026-04-07


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07515963

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07515963, "FULIRI Plus Targeted Therapy for First-line Conversion Therapy of Colorectal Cancer Liver Metastases.". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT07515963. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*